The impact of migraine on work, family, and leisure among young women - a multinational study

被引:42
作者
Dueland, AN
Leira, R
Burke, TA
Hillyer, EV
Bolge, S
机构
[1] Sandvika Neurol Serv, Sandvika, Norway
[2] Hosp Clin Univ, Serv Neurol, Coruna, Spain
关键词
functional disability; headache; migraine; productivity; triptans; work;
D O I
10.1185/030079904X3357
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective: To assess the impact of migraine on work, family, and leisure among young women who were employed full or part time, or as a fulltime student. Research design and methods: This cross-sectional telephone survey with 6-month recall was conducted in Israel and eight European countries (Finland, Germany, Greece, Italy, Norway, Spain, Sweden, and The Netherlands). Random-digit dialing was used to identify study participants: women 18-35 years of age with migraine, who used medication to treat their migraine, and who were employed or full-time students. Results: Of 1810 participants, 42% self-reported having a physician diagnosis of migraine. During the prior 6 months, 46% of participants missed at least 1 day of work or school and 74% were prevented from functioning fully at work or school because of migraine. Mean work/school absenteeism due to migraine was 1.9 days over 6 months (range, 0.8 days in Sweden to 2.8 days in Norway). Over half of participants reported one or more occurrences of being unable to spend time with family or friends (62%) or being unable to enjoy recreational or leisure activities (67%) because of migraine. The percentage of study participants using triptans was lowest in southern Europe and highest in the Nordic countries, ranging from 1 % in Greece to 50% in Sweden. Country, age, marital status, physician diagnosis of migraine, and number of migraines or severe headaches in the prior year were independent predictors of the mean number of days of migraine-related work loss. Migraine-related work loss was lowest in Sweden and greatest in Greece, Israel, and The Netherlands. Higher work loss was recorded for those 18-24 years of age; those who were separated, widowed, or divorced; those with migraine diagnosed by a physician; and those with more frequent migraines or severe headaches ( greater than or equal to 24/year). The 6-month recall period used when estimating patient-reported work loss, and identifying participants with migraine based on self-reported migraine or severe headache, were the most important limitations of the study. Conclusions: We found substantial migrainerelated impairment of productivity at work and school as well as of family and leisure time among young women in Israel and eight European countries.
引用
收藏
页码:1595 / 1604
页数:10
相关论文
共 31 条
[1]  
Baos V, 2003, INT J CLIN PRACT, V57, P761
[2]   Pharmaceuticals and worker productivity loss: A critical review of the literature [J].
Burton, WN ;
Morrison, A ;
Wertheimer, AI .
JOURNAL OF OCCUPATIONAL AND ENVIRONMENTAL MEDICINE, 2003, 45 (06) :610-621
[3]   Sumatriptan injection reduces productivity loss during a migraine attack - Results of a double-blind, placebo-controlled trial [J].
Cady, RC ;
Ryan, R ;
Jhingran, P ;
O'Quinn, S ;
Pait, DG .
ARCHIVES OF INTERNAL MEDICINE, 1998, 158 (09) :1013-1018
[4]   Economic and social impact of migraine [J].
Clarke, CE ;
MacMillan, L ;
Sondhi, S ;
Wells, NEJ .
QJM-MONTHLY JOURNAL OF THE ASSOCIATION OF PHYSICIANS, 1996, 89 (01) :77-84
[5]  
Cull RE, 1992, BRIT J EC, V2, P103
[6]   Work and productivity loss in the rizatriptan multiple attack study [J].
Dasbach, EJ ;
Carides, GW ;
Gerth, WC ;
Santanello, NC ;
Pigeon, JG ;
Kramer, MS .
CEPHALALGIA, 2000, 20 (09) :830-834
[7]   Validation of a migraine work and productivity loss questionnaire for use in migraine studies [J].
Davies, GM ;
Santanello, N ;
Gerth, W ;
Lerner, D ;
Block, GA .
CEPHALALGIA, 1999, 19 (05) :497-502
[8]   The economic burden of migraine to society [J].
Ferrari, MD .
PHARMACOECONOMICS, 1998, 13 (06) :667-676
[9]   The multinational impact of migraine symptoms on healthcare utilisation and work loss [J].
Gerth, WC ;
Carides, GW ;
Dasbach, EJ ;
Visser, WH ;
Santanello, NC .
PHARMACOECONOMICS, 2001, 19 (02) :197-206
[10]   Improvement in health-related quality of life with rizatriptan 10mg compared with standard migraine therapy [J].
Gerth, WC ;
Ruggles, KH ;
Stark, SR ;
Davies, GM ;
Santanello, NC .
CLINICAL DRUG INVESTIGATION, 2001, 21 (12) :853-860